Effect of weekly 17-hydroxyprogesterone caproate on small for gestational age among pregnant women with HIV in Zambia.

Conner, MG ; Vwalika, B ; et al.

In: AIDS (London, England), Jg. 36 (2022-11-15), Heft 14, S. 2079-2081

Online academicJournal

Zugriff:

Full Text Finder (Volltext)

The IPOP trial demonstrated a reduced risk of severe small for gestational age among infants born to women with HIV who received weekly intramuscular 17 alpha-hydroxyprogesterone caproate. This secondary analysis examined the 17P treatment effect in subgroups of maternal BMI, parity, timing of antiretroviral therapy (ART) initiation, and ART regimen. We found that 17P was more effective among nulliparous women, women who started ART before pregnancy, and those taking protease inhibitors.

Titel:	Effect of weekly 17-hydroxyprogesterone caproate on small for gestational age among pregnant women with HIV in Zambia.
Autor/in / Beteiligte Person:	Conner, MG ; Vwalika, B ; Freeman, BL ; Sebastião, YV ; Mabula-Bwalya, CM ; Cole, SR ; Stringer, EM ; Kasaro, MP ; Stringer, JSA ; Price, JT
Link:	Full Text Finder (Volltext)
Zeitschrift:	AIDS (London, England), Jg. 36 (2022-11-15), Heft 14, S. 2079-2081
Veröffentlichung:	1998- : London, England : Lippincott Williams & Wilkins ; <i>Original Publication</i>: London : Gower Academic Journals, c1987-, 2022
Medientyp:	academicJournal
ISSN:	1473-5571 (electronic)
DOI:	10.1097/QAD.0000000000003362
Schlagwort:	Female Humans Infant Pregnancy 17-alpha-Hydroxyprogesterone Gestational Age Hydroxyprogesterones Pregnant Women Zambia 17 alpha-Hydroxyprogesterone Caproate adverse effects HIV Infections drug therapy Premature Birth
Sonstiges:	Nachgewiesen in: MEDLINE Sprachen: English Publication Type: Clinical Trial; Journal Article; Research Support, N.I.H., Extramural Language: English [AIDS] 2022 Nov 15; Vol. 36 (14), pp. 2079-2081. <i>Date of Electronic Publication: </i>2022 Aug 18. MeSH Terms: 17 alpha-Hydroxyprogesterone Caproate* / adverse effects ; HIV Infections* / drug therapy ; Premature Birth* ; Female ; Humans ; Infant ; Pregnancy ; 17-alpha-Hydroxyprogesterone ; Gestational Age ; Hydroxyprogesterones ; Pregnant Women ; Zambia References: Wedi CO, Kirtley S, Hopewell S, Corrigan R, Kennedy SH, Hemelaar J. Perinatal outcomes associated with maternal HIV infection: a systematic review and meta-analysis . Lancet HIV 2016; 3:e33–48. ; Li N, Sando MM, Spiegelman D, Hertzmark E, Liu E, Sando D, et al. Antiretroviral therapy in relation to birth outcomes among HIV-infected women: a cohort study . J Infect Dis 2016; 213:1057–1064. ; Mohammadi H, Papp E, Cahill L, Rennie M, Banko N, Pinnaduwage L, et al. HIV antiretroviral exposure in pregnancy induces detrimental placenta vascular changes that are rescued by progesterone supplementation . Sci Rep 2018; 8:6552. ; Price JT, Vwalika B, Freeman BL, Cole SR, Saha PT, Mbewe FM, et al. Weekly 17 alpha-hydroxyprogesterone caproate to prevent preterm birth among women living with HIV: a randomised, double-blind, placebo-controlled trial . Lancet HIV 2021; 8:10. ; Price JT, Vwalika B, Freeman BL, Cole SR, Mulenga HB, Winston J, et al. Intramuscular 17-hydroxyprogesterone caproate to prevent preterm birth among HIV-infected women in Zambia: study protocol of the IPOP randomized trial . BMC Pregnancy Childbirth 2019; 19:81. ; Villar J, Cheikh Ismail L, Victora CG, Ohuma EO, Bertino E, Altman DG, et al. International standards for newborn weight, length, and head circumference by gestational age and sex: the Newborn Cross-Sectional Study of the INTERGROWTH-21st Project . Lancet 2014; 384:857–868. Grant Information: R01 HD087119 United States HD NICHD NIH HHS; D43 TW010558 United States TW FIC NIH HHS; D43 TW009340 United States TW FIC NIH HHS; K01 TW010857 United States TW FIC NIH HHS; T32 HD075731 United States HD NICHD NIH HHS Substance Nomenclature: 276F2O42F5 (17 alpha-Hydroxyprogesterone Caproate) ; 68-96-2 (17-alpha-Hydroxyprogesterone) ; 0 (Hydroxyprogesterones) Entry Date(s): Date Created: 20221028 Date Completed: 20221101 Latest Revision: 20231116 Update Code: 20240513 PubMed Central ID: PMC9624437

Klicken Sie ein Format an und speichern Sie dann die Daten oder geben Sie eine Empfänger-Adresse ein und lassen Sie sich per Email zusenden.

BibTeX Citavi, JabRef, u.a.
(Literaturverwaltung)

PDF kein Volltext!
(Merkzettel, Notizen)

RIS Endnote, Citavi u.a.
(Literaturverwaltung)

MODS
(XML zur Weiterverarbeitung)

oder

Wählen Sie das für Sie passende Zitationsformat und kopieren Sie es dann in die Zwischenablage, lassen es sich per Mail zusenden oder speichern es als PDF-Datei.

Gewünschter Zitations-Stil:

oder

Bitte prüfen Sie, ob die Zitation formal korrekt ist, bevor Sie sie in einer Arbeit verwenden. Benutzen Sie gegebenenfalls den "Exportieren"-Dialog, wenn Sie ein Literaturverwaltungsprogramm verwenden und die Zitat-Angaben selbst formatieren wollen.